Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL28759593 | 0.81 | MEN1 (0.32) | — | |
| SCHEMBL9809435 | 0.79 | — | — | |
| SCHEMBL1355604 | 0.75 | — | — | |
| Ethylene SCHEMBL28897425 | 0.71 | SLC22A6 (0.39) | SLC22A6 | |
| SCHEMBL6632566 | 0.71 | — | — | |
| SCHEMBL2469912 | 0.71 | — | — | |
| SCHEMBL8386319 | 0.71 | — | — | |
| SCHEMBL1728414 | 0.71 | SLC22A6 (0.41) | SLC22A6 | |
| SCHEMBL4757103 | 0.69 | TP53 (0.40) | SLC22A6CA5ACA5B | |
| SCHEMBL7412312 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10898580-B2 | Isoquinolidinobenzodiazepines | CELLERANT THERAPEUTICS, INC. (US) | 2021-01-26 | — | — | US | claimed |
| US-20200061079-A1 | ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS | THE CHEMISTRY RESEARCH SOLUTIONS LLC | 2020-02-27 | — | — | US | claimed |
| EP-2562294-B1 | PLATING BATH AND METHOD | ROHM & HAAS ELECT MAT (US) | 2019-09-25 | — | — | EP | claimed |
| EP-3522932-A1 | ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS | Cellerant Therapeutics, Inc. (US) | 2019-08-14 | — | — | EP | claimed |
| EP-3036224-B1 | POLYMERS CONTAINING BENZIMIDAZOLE MOIETIES AS LEVELERS | ROHM & HAAS ELECT MAT (US) | 2019-04-17 | — | — | EP | claimed |
| US-20180280529-A1 | ISOQUINOLIDINOBENZODIAZEPINES | CELLERANT THERAPEUTICS INC (US) | 2018-10-04 | — | — | US | claimed |
| US-20180177795-A1 | ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS | CELLERANT THERAPEUTICS, INC. | 2018-06-28 | — | — | US | claimed |
| US-9974864-B2 | Isoquinolidinobenzodiazepines | CELLERANT THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | claimed |
| WO-2018071455-A1 | ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS | CELLERANT THERAPEUTICS, INC. (US) | 2018-04-19 | — | — | WO | claimed |
| WO-2018053552-A2 | ISOQUINOLIDINOBENZODIAZEPINES | CELLERANT THERAPEUTICS, INC. (US) | 2018-03-22 | — | — | WO | claimed |
| EP-3271359-A1 | ISOQUINOLIDINOBENZODIAZEPINES | Cellerant Therapeutics, Inc. (US) | 2018-01-24 | — | — | EP | claimed |
| US-20170157265-A1 | ISOQUINOLIDINOBENZODIAZEPINES | CELLERANT THERAPEUTICS, INC. | 2017-06-08 | — | — | US | claimed |
| US-9504694-B2 | Isoquinolidinobenzodiazepines | CELLERANT THERAPEUTICS, INC. (US) | 2016-11-29 | — | — | US | claimed |
| WO-2016149546-A1 | ISOQUINOLIDINOBENZODIAZEPINES | CELLERANT THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | claimed |
| US-20160271142-A1 | ISOQUINOLIDINOBENZODIAZEPINES | CELLERANT THERAPEUTICS, INC. | 2016-09-22 | — | — | US | claimed |
| WO-2023046710-A1 | FLOW BATTERIES WITH A NEGOLYTE BASED ON VIOLOGEN AND A HYDROALCOHOLIC SOLVENT | IFP Energies Nouvelles (FR) | 2023-03-30 | — | — | WO | disclosed |
| US-10898580-B2 | Isoquinolidinobenzodiazepines | CELLERANT THERAPEUTICS, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| EP-0273115-A2 | Chemiluminescent acridinium and phenanthridinium salts | ABBOTT LABORATORIES (US) | 1988-07-06 | — | — | EP | disclosed |
| CN-85105316-A | The preparation method of the novel 3-sulfopropyl betaine that replaces on the 2-position | — | 1987-01-07 | — | — | CN | disclosed |
| US-4332889-A | IMPROVED SENSITIVITY, STORAGE STABILITY | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1982-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177795-A1 | ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS | BCL6B, HTR2B, IDO1 | SLC22A6 3129/4885CA5A 2866/4885CA5B 1782/4885 |
| US-20180280529-A1 | ISOQUINOLIDINOBENZODIAZEPINES | BCR, IGLV6-57, GABRA4 | SLC22A6 1831/4885CA5A 2924/4885CA5B 2348/4885 |
| US-20200061079-A1 | ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS | BCL6B, HTR2B, IDO1 | SLC22A6 3129/4885CA5A 2866/4885CA5B 1782/4885 |
| US-20170157265-A1 | ISOQUINOLIDINOBENZODIAZEPINES | BCR, IGLV6-57, GABRA4 | SLC22A6 1831/4885CA5A 2924/4885CA5B 2348/4885 |
| US-10898580-B2 | Isoquinolidinobenzodiazepines | BCR, IGLV6-57, GABRA4 | SLC22A6 1831/4885CA5A 2924/4885CA5B 2348/4885 |
| US-20160271142-A1 | ISOQUINOLIDINOBENZODIAZEPINES | BCR, IGLV6-57, GABRA4 | SLC22A6 1831/4885CA5A 2924/4885CA5B 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.